Conference Details - Overview
Continuing Education Information
Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource designates this educational activity for a maximum of 7 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses: Physicians’ Education Resource is an approved provider of continuing nursing education by the Texas Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Physicians’ Education Resource provides up to 7 contact hours for completion of this educational activity.
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA category 1 CME credit for the PRA from organizations accredited by the ACCME.
Eighth International Symposium on Supportive Care in Oncology: Cancer Management in the Era of Targeted Agents
New York Marriott Downtown
New York, NY
February 20, 2010
Conference Overview
Summary and Purpose
CME- and CNE-Certified Symposium
Oncology professionals need to recognize the unique adverse events associated with cancer treatment options in order to improve patient outcomes by limiting side effects and thus increasing the ability of patients to complete full courses of therapy. Additional improvements can be achieved by recognizing key supportive care measures for cancer itself. It is imperative that oncology professionals involved in the day-to-day care of patients recognize these properties and incorporate complementary supportive care treatments to monitor, assess, and manage these symptoms as these drugs continue to be used in earlier stages of disease for longer periods of time.
The Eighth International Symposium on Supportive Care in Oncology is designed to educate oncology professionals on the state-of-the-art options for supportive care required during the treatment of specific tumor types. Not only will participants learn about improvements in the management of chemotherapy- and disease-related conditions, such as gastrointestinal toxicities, myelosuppression, and neurologic symptoms, but also significant time will be focused on the management of targeted agent–related class effects, such as skin rash and other cutaneous adverse events, cardiotoxicity, hypertension, and bleeding complications.
Target Audience
This educational program is directed toward medical, surgical, and radiation oncologists; hematologists; nurse practitioners; and oncology nurses interested in understanding the causes of treatment-related adverse events and learning how to prevent and manage them. Fellows, physician assistants, pharmacists, and other health care professionals interested in supportive care in oncology are also invited to attend.Learning Objectives
At the conclusion of this symposium, you should be able to:
- Outline the management of adverse events resulting from therapy with targeted agents such as those targeting EGFR and angiogenesis
- Evaluate the management of chemotherapy-associated adverse events
- Assess the efficacy of treatment strategies to minimize the adverse effects of cancer therapy on the neurologic system
- Summarize the adverse events associated with targeted agents such as PARP inhibitors
- Appraise the safety and efficacy of management strategies for cancer- and treatment-related hematologic adverse events
- Outline treatment strategies for managing bone-related adverse events
Educational Grants
An educational grant for this activity was provided by:
- Merck Oncology
- Eisai Inc.
- sanofi-aventis U.S.